Zai Lab Launches Global Phase 3 Clinical Trial of DLL3 ADC Zocilurtatug Pelitecan, Signaling Full-Scale International Expansion
Business Expansion Based on License‑In Model
Since its founding in 2014, Zai Lab has grown by licensing in drug candidates from global big‑pharma companies and commercializing them in Greater China. Notable examples include GSK’s ovarian cancer therapy Zejula (generic name niraparib) and Bristol‑Myers Squibb’s schizophrenia drug Cobenfy (generic name zanolmelin‑tropium). Using this model, the company generated $460 million in revenue last year solely from China, but it is now seeking to overcome domestic market limitations by transforming into a multinational pharmaceutical organization.
Entry into Global Clinical Development and Core Pipeline
The lead candidate driving Zai Lab’s growth is the DLL3‑targeted antibody‑drug conjugate (ADC) Zocilurtatug Pelitecan (development code ZL‑1310), exclusively licensed from MediLink Therapeutics. In Phase 1b/2 data presented at the AACR 2026 meeting, the ADC achieved an objective response rate (iORR) of 53.7 % in patients with extensive‑stage small‑cell lung cancer (ES‑SCLC) brain metastases, and a 62.5 % response rate in the 1.6 mg/kg cohort, demonstrating robust blood‑brain barrier penetration. In a separate study of 34 patients with extrapulmonary neuroendocrine carcinoma (epNEC), the drug produced a response rate of 38.2 % and a disease control rate (DCR) of 55.9 %, earning Fast Track designation from the FDA.
Paradox of the Chinese Market and the Imperative of U.S. Entry
Although China’s biotech ecosystem is expanding rapidly, it faces a growth inflection point due to limited global regulatory expertise and financing channels. Stringent domestic price controls and demanding IPO requirements make revenue generation outside of out‑licensing challenging. The U.S. market, by contrast, can deliver multi‑hundred‑million‑dollar revenues from a single product, making the ongoing global Phase 3 trial (NCT07218146) essential for Zai Lab. Consequently, the company’s strategy—to reduce reliance on domestic CROs and strengthen a U.S.-based R&D operation—represents a survival play to overcome capital and regulatory barriers.
Outlook for Asia‑Pacific Biotech Competitiveness
Zai Lab differentiates itself with a vertically integrated clinical network that leverages hundreds of in‑house investigators to collaborate directly with hospitals across China. This agility has led Citi analysts to project peak global sales of Zocilurtatug Pelitecan at roughly $500 million, surpassing the company’s total current sales in China. Zai Lab’s trajectory offers a new self‑sustaining multinational model for Chinese biotech firms confronting funding constraints and the U.S. Biosecure Act. It is also expected to act as a positive catalyst for the influx of innovative platforms from neighboring Asian markets such as South Korea and Japan.
Zai Lab is accelerating its transition from a license‑in‑centric business model to an independent multinational pharmaceutical company by advancing the DLL3‑targeted ADC Zocilurtatug Pelitecan into global Phase 3 trials. The objective response rate of 62.5 % reported at AACR 2026 in ES‑SCLC patients with brain metastases, and the 38.2 % response rate observed in epNEC, demonstrate best‑in‑class commercial potential. Citi estimates the drug’s peak global sales at approximately $500 million annually, exceeding Zai Lab’s existing total China revenue of $460 million and providing a powerful growth engine. In the medium to long term, the candidate is expected to narrow the commercialization gap with leading competitors such as Amgen’s DLL3‑targeted bispecific antibody Tarlatamab (brand name Imdeltra), and to serve as a pivotal inflection point for Chinese biotech firms seeking to integrate into global value chains despite geopolitical risks such as the Biosecure Act.